Survival in pulmonary arterial hypertension: A reappraisal of the NIH risk stratification equation

European Respiratory Journal

Volumn 35, Issue 5, 2010, Pages 1079-1087

  Thenappan, T ^a   Shah, S J ^b   Rich, S ^a   Tian, L ^b   Archer, S L ^a   Gomberg Maitland, M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

National Institutes of Health equation; Prognosis; Pulmonary arterial hypertension; Survival

Indexed keywords

ANOREXIGENIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; FAMILIAL DISEASE; FEMALE; HEART INDEX; HEART RIGHT ATRIUM PRESSURE; HUMAN; IDIOPATHIC DISEASE; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH ORGANIZATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK ASSESSMENT; SURVIVAL RATE; WORLD HEALTH ORGANIZATION;

FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; REGRESSION ANALYSIS; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SURVIVAL ANALYSIS; UNITED STATES;

EID: 77951961897     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00072709     Document Type: Article

References (28)

1. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-1665.
2. Rich S, Dantzker R, Ayres S, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107: 216-223. (Pubitemid 17137857)
3. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
4. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with treprostinil. Eur Respir J 2006; 28: 1195-1203. (Pubitemid 44883856)
5. Kuhn K, Byrne D, Arbogast PG, et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003; 167: 580-586.
6. McLaughlin VV. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur J Clin Invest 2006; 36: Suppl. 3, 10-15. (Pubitemid 44179776)
7. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.
8. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with firstline bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25: 244-249. (Pubitemid 40246523)
9. Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27: 589-595.
10. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131: 1917-1928. (Pubitemid 46981654)
11. Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007; 30: 1103-1110.
12. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126:Suppl. 1, 14S-34S. (Pubitemid 38932340)
13. Souza R, Humbert M, Sztrymf B, et al. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 2008; 31: 343-348.
14. Patterson JA, Naughton J, Pietras RJ, et al. Treadmill exercise in assessment of the functional capacity of patients with cardiac disease. Am J Cardiol 1972; 30: 757-762.
15. Gomberg-Maitland M, Huo D, Benza RL, et al. Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension. J Heart Lung Transplant 2007; 26: 732-738. (Pubitemid 47001713)
16. Shah SJ, Thenappan T, Rich S, et al. Value of exercise treadmill testing in the risk stratification of patients with pulmonary hypertension. Circ Heart Fail 2009; 2: 278-286.
17. Nootens M, Schrader B, Kaufman E, et al. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest 1995; 107: 54-57.
18. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111. (Pubitemid 40847788)
19. Carroll KJ. On the use and utility of the Weibull model in the analysis of survival data. Control Clin Trials 2003; 24: 682-701.
20. Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005; 60: 1025-1030. (Pubitemid 41705471)
21. Sandoval J, Bauerle O, Palomar A, et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 1994; 89: 1733-1744.
22. Fuster V, Steel P, Edwards W, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-587. (Pubitemid 14020655)
23. Rich S, Kaufman E, Levy P. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
24. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788. (Pubitemid 34925627)
25. Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394-403.
26. Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007; 153: 1037-1047. (Pubitemid 46809838)
27. Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 344-350. (Pubitemid 36269414)
28. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006; 54: 3043-3050. (Pubitemid 44497786)